As we have said for quite some time,
"when the penny drops" ,
a valuation that reflects future revenues across the platforms will start to build. Proof of concept for the first B Cell vaccine is essentially proof of concept for many more to follow.
Davy: "We are also definitely (in my view) "undervalued" and "not well understood by the market."
Have you given much consideration Dave to a break down of "Sum of the Parts" Total Valuation ?
At today's price based off the Turnstone/Takeda pre clinical deal CF33 might be considered valued at half fair value. Leaving the further advanced HerVax at late stage Ph 2 , and Pd1 Vaxx with preliminary Ph1 safety showing ,valued at zero. Absurd really. All are game changers.
Personally i don't see any upside or understanding from the Mimitope platform factored in at this level.
Media Thread, page-1185
-
- There are more pages in this discussion • 14,468 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $371.8M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.8¢ | $521.9K | 10.58M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 1612511 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 3882781 | 14 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |